FIELD: pharmaceuticals.
SUBSTANCE: group of inventions discloses self-microemulsifying drug delivery system (SMEDDS) for treating or preventing liver disease in a subject containing CRV431 or a pharmaceutically acceptable salt thereof, where SMESDLS also contains vitamin E, Mayzin® CC, propylene glycol, Transcutol®, ethanol and Cremofor® RH40 in a mass ratio of 1/1.5/2.5/5/2.4/5, respectively. Also the following is disclosed: a method of treating or preventing liver disease in a subject in need thereof and the use of a therapeutically effective amount of a self-microemulsifying drug delivery system (SMEDDS).
(CRV431)
EFFECT: ensuring good solubility of the cyclosporine A derivative (for example, CRV431) and significant exposure in the blood in humans after a single oral dose in healthy subjects.
44 cl, 10 tbl, 8 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION OF TAXOIDS | 2011 |
|
RU2603833C2 |
| INJECTION DRUG FORM FOR TREATMENT AND PREVENTION OF LIVER DISEASES IN ANIMALS | 2012 |
|
RU2504347C1 |
| PHARMACEUTICAL COMPOSITION COMPRISING CYCLOSPORINE AS ACTIVE COMPONENT | 2000 |
|
RU2207870C2 |
| HIGHLY CONCENTRATED COMPOSITION | 2016 |
|
RU2731564C2 |
| PHARMACEUTICAL COMPOSITION, PRODUCT OF TRANSESTERIFICATION OF CORN OIL WITH GLYCEROL AND METHOD OF ITS PREPARING | 1992 |
|
RU2143919C1 |
| CYCLOSPORIN-CONTAINING PHARMACEUTICAL COMPOSITION, METHOD OF SOFT GELATIN CAPSULE PREPARING | 1998 |
|
RU2178293C2 |
| INJECTABLE DOSAGE FORM FOR THE TREATMENT AND PREVENTION OF LIVER DISEASES IN ANIMALS | 2021 |
|
RU2800150C2 |
| CYTARABINE CONJUGATES FOR TREATING CANCER | 2016 |
|
RU2708672C1 |
| INHALATION DOSAGE FORM OF RAPAMYCIN FOR TREATING PULMONARY HYPERTENSION | 2015 |
|
RU2732908C2 |
| RAPAMYCIN-CONTAINING COMPOSITION ADMINISTERED BY INHALATION FOR TREATING AGE-RELATED DISEASES | 2015 |
|
RU2718583C2 |
